Fascination About GW7647
All enrolled people who acquired a minimum of a person dose of zosuquidar or placebo for the duration of induction were being monitored for the incidence of adverse situations (439 individuals, 219 on zosuquidar and 210 on placebo). The most common adverse functions were being connected with the duration of extended and major myelosuppression as is